POTASSIUM PHOSPHATES Drug Patent Profile
✉ Email this page to a colleague
When do Potassium Phosphates patents expire, and when can generic versions of Potassium Phosphates launch?
Potassium Phosphates is a drug marketed by Am Regent, Amneal, Cmp Dev Llc, and Fresenius Kabi Usa. and is included in four NDAs. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in POTASSIUM PHOSPHATES is potassium phosphate, dibasic; potassium phosphate, monobasic. There are two hundred and forty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the potassium phosphate, dibasic; potassium phosphate, monobasic profile page.
DrugPatentWatch® Generic Entry Outlook for Potassium Phosphates
Indicators of Generic Entry
Summary for POTASSIUM PHOSPHATES
International Patents: | 1 |
US Patents: | 1 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 3 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in POTASSIUM PHOSPHATES? | POTASSIUM PHOSPHATES excipients list |
DailyMed Link: | POTASSIUM PHOSPHATES at DailyMed |
Recent Clinical Trials for POTASSIUM PHOSPHATES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mahidol University | N/A |
Pharmacology for POTASSIUM PHOSPHATES
Drug Class | Osmotic Laxative Potassium Salt |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
US Patents and Regulatory Information for POTASSIUM PHOSPHATES
POTASSIUM PHOSPHATES is protected by one US patents and two FDA Regulatory Exclusivities.
Patents protecting POTASSIUM PHOSPHATES
Potassium phosphates composition for injection
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
FDA Regulatory Exclusivity protecting POTASSIUM PHOSPHATES
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
International Patents for POTASSIUM PHOSPHATES
See the table below for patents covering POTASSIUM PHOSPHATES around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2020081118 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for POTASSIUM PHOSPHATES
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
3141251 | 301099 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
0733366 | SPC/GB98/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |